Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
← catalyst calendarNCT07089576 · readout ≤ 619 d
Sponsored by Artivion Inc. (industry) · AORT — their whole pipeline →. With Bright Research Partners.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
132estimated
Sites
21
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-04 | actual | When the study began enrolling |
| Primary completion | Apr 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Aortic Arch Aneurysm
- Aortic Arch Dissection
- Chronic Aortic Dissection
- Acute Aortic Dissection
Intervention
- Device: Arcevo™ LSA Hybrid Stent Graft System
Primary outcome
what the primary-completion date above is the date OFComposite Rate of Patients Free From ≥1 Major Adverse Event
measured 1 year post-index procedure of LSA stent graft implant
Permalink · AORT's whole pipeline · Catalyst calendar · Every registered study · What changed